Navigation Links
Conatus Pharmaceuticals Inc. Files Registration Statement for Proposed Initial Public Offering
Date:6/14/2013

SAN DIEGO, June 14, 2013 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not been determined. All shares of the common stock to be sold in the offering will be offered by Conatus.

Stifel and Piper Jaffray & Co. are acting as joint book-running managers for the offering. JMP Securities LLC is acting as co-lead manager and SunTrust Robinson Humphrey, Inc. is acting as co-manager for the offering. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by calling (415) 364-2720 or by emailing SyndicateOps@stifel.com, and from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by calling (800) 747-3924 or by emailing prospectus@pjc.com.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful,
'/>"/>

SOURCE Conatus Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Conatus Pharmaceuticals Appoints Daniel Ripley As Head Of Corporate Development
2. Arena Pharmaceuticals to Present at the 2013 Wells Fargo Securities Healthcare Conference
3. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
4. Omthera Pharmaceuticals Announces Record Date and Meeting Date for Special Meeting of Stockholders
5. Chronic Kidney Disease: Reducing Risks of Progression-- Prismic Pharmaceuticals Secures Exclusive Licensing Rights
6. Anthera Pharmaceuticals Announces Personnel Changes
7. Zydus Pharmaceuticals USA Inc. Issues Voluntary Nationwide Recall of Warfarin 2 mg Tablets, Lot MM5767, Expiration Date June 2014, Due to Oversized Tablets
8. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
9. Access Pharmaceuticals Signs US License Agreement With AMAG Pharmaceuticals For MuGard
10. HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2b Clinical Study of HQK-1001 in Patients with Sickle Cell Disease
11. Oramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 Adaptive Biotechnologies, a clinical stage diagnostics ... the adaptive immune system, is pleased to announce the ... Officer (CCO). The addition of Brain to the Company,s ... leading global healthcare companies, including Dean Schorno ... Genomic Health and Sean Nolan (CTO) from ...
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, ... Boston and their first West Coast location in ... Street in Boston , and will house product ... Southern California office will be located at ... the demands of customers nationwide.  Both new locations will be ...
(Date:9/16/2014)... Sept. 16, 2014  Formex, LLC ("Formex"), ... that Mr. Greg Weilersbacher joined Formex as Director ... Greg Weilersbacher has ... focused expertise in Quality Assurance, Facility Validation, ... Weilersbacher brings to Formex a diverse wealth ...
Breaking Medicine Technology:Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... R.I., Aug. 16, 2011 Medicare Part D beneficiaries ... pay 100 percent of previously subsidized prescription costs, are ... are to switch to more affordable or generic medications, ... concludes. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) The ...
... Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... Phase III clinical studies in patients with refractory chronic ... of the American Medical Association ( JAMA ). ... significant and sustained reductions in uric acid levels along ...
Cached Medicine Technology:CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 2CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 2Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 5Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 6Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 7Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 8
(Date:9/16/2014)... pain clinic as a testing ground, researchers at Johns ... by Toyota in Japan can substantially reduce patient wait ... residents. , In a report on the pilot study, ... the researchers adopted the so-called "Just-in-Time" training and inventory ... to stem waste and keep complicated operations from bottlenecking. ...
(Date:9/16/2014)... Va. (PRWEB) September 16, 2014 ... through predictive analytics and targeted clinical programs, today ... announced changes support the Company’s drive to improve ... and targeted clinical programs. On September 2, 2014, ... company, Millennium Health, announced that RxAnte founder and ...
(Date:9/16/2014)... Thompson HealthDay Reporter MONDAY, ... strong heart fitness can delay a man,s onset of age-related ... suggests. Blood pressure naturally increases as people grow older ... with strong cardio-fitness don,t start drifting toward high blood pressure ... usually experience the early signs of high blood pressure in ...
(Date:9/16/2014)... early-stage lung cancer who receive stereotactic body radiation ... 40 percent, according to research presented today at ... Annual Meeting. Such a positive survival rate is ... poor tumor control for patients with inoperable lung ... 0236, originally published in 2010 , and also ...
(Date:9/16/2014)... West Orange, NJ. September 16, 2014. Kessler Foundation ... of slowed processing speed in the executive deficits ... "Does slowed processing speed account for executive deficits ... structural neuroimaging," was published online ahead of print ... The authors are Victoria Leavitt, PhD, ...
Breaking Medicine News(10 mins):Health News:Patients waiting too long to see doctor? Try 'just-in-time' management methods, researchers urge 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 2Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 3Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 3
... ... in designing cutting-edge training facility for Kodak Dental Systems that features practice management ... ... August 4, 2009 -- Advanced Automation, a leader in comprehensive IT solutions and ...
... , ROSEMONT, Ill., Aug. 4 ... such anesthetic drugs as Diprivan (propofol) by the late Michael Jackson, ... agents. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20050125/CGTU021LOGO ... and Maxillofacial Surgeons (AAOMS) and its 8,500 fellows and members who ...
... , , , ... (Pink Sheets: NXCO), developer of next generation digital media protection ... , a website that provides authors in the self-help/motivational market ... their downloadable materials. AmnestyQuest.com is a partnership between Nexicon and ...
... MINNEAPOLIS, Aug. 4 Court ordered Class Notice in Curtis, et al., ... , court File No. 27-CV-01-18042 (action filed 11/28/01). , , ... at any time before November 30, 2004, this class action notice may affect ... the marketing, advertising and promotion of Marlboro Lights cigarettes is pending in Hennepin ...
... , AVENTURA, Fla., Aug. 4 ... of highly specialized, nationally recognized orthopedic surgeons who have agreed ... business model of Centers of Excellence with Global Convenience(TM) ... orthopedic procedures domestically and abroad. The team represents a total ...
... ... has introduced a new technology offering including their new Scoreboard application. ... at a glance screen showing key business indicators updated in real-time. ... or both. The Scoreboard will be available to clients that either ...
Cached Medicine News:Health News:New Kodak Training Facility Showcases the Latest in Dental Technology, Solutions from Advanced Automation: Networking Solutions, Dental Practice Management and Dental X-Ray Integration 2Health News:New Kodak Training Facility Showcases the Latest in Dental Technology, Solutions from Advanced Automation: Networking Solutions, Dental Practice Management and Dental X-Ray Integration 3Health News:American Association of Oral and Maxillofacial Surgeons Says Only Trained Dental and Medical Practitioners Should Administer and Monitor Anesthesia 2Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 2Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 3Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 4Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 5Health News:Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A. 2Health News:Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A. 3Health News:Mobile Surgery International Assembles Team of Nationally Recognized Orthopedic Surgeons 2Health News:Mobile Surgery International Assembles Team of Nationally Recognized Orthopedic Surgeons 3Health News:DME Billing Lets Home Care Providers Know How They are Doing in Real Time 2Health News:DME Billing Lets Home Care Providers Know How They are Doing in Real Time 3
ACMI™ COAG Bipolar Laparoscopy Probes provide 360 of hemostatis, bipolar safety, blunt dissection, irrigation, and suction in one instrument....
An In Vitro Nucleic Acid Hybridization Assay with Signal Amplification using Microplate Chemiluminescence for the Qualitative Detection of Human Papillomavirus (HPV) Types 16, 18, 31, 33, 35, 39, 45,...
... first time in the world, there is a ... to diagnose VVC in female patients. CanDia5® is ... detect the Candida antigens almost instantaneously (within 5 ... blood. There is no similar POC product for ...
... test for Candida albicans in only ... utilizes two enzyme color reactions to ... to read. AlbiQuicktm is performed on ... wells. Incubation time is only five ...
Medicine Products: